Wiley
Wiley.com
Print this page Share

Aspartic Acid Proteases as Therapeutic Targets

Arun K. Ghosh (Editor), Raimund Mannhold (Series Editor), Hugo Kubinyi (Series Editor), Gerd Folkers (Series Editor)
ISBN: 978-3-527-31811-7
Hardcover
640 pages
October 2010
US $210.00 Add to Cart

This price is valid for United States. Change location to view local pricing and availability.

Aspartic Acid Proteases as Therapeutic Targets (3527318119) cover image
Other Available Formats: E-book

OVERVIEW OF ASPARTIC ACID PROTEASES
Introduction to the Aspartic Proteases Family
Aspartic Acid Proteases, Structure, Function and Inhibition
Human Aspartic Proteinases
Structure-based Drug Design Strategies for the Inhibition of Aspartic Acid Proteases

HIV-1 PROTEASE FOR THE TREATMENT OF HIV/AIDS
HIV-1 Protease: Role in Viral Replication, Protein-Ligand X-ray Crystal Structures and Inhibitor Design
First generation FDA Approved HIV protease inhibitors
Second-Generation Approved HIV Protease Inhibitors for Treatment of HIV/AIDS
Design, Conception and Clinical Development of Darunavir, a HIV-1 Protease Inhibitor to Combat Drug Resistance
Development of Protease Inhibitors and Challenges to Drug-Resistance of HIV-1

RENIN FOR TREATMENT OF HYPERTENSION
Discovery and Development of Aliskiren, the First-in-Class Direct Renin Inhibitor for the Treatment of Hypertension
Evolution of Diverse Classes of Renin Inhibitors Through the Years

GAMMA-SECRETASE FOR TREATMENT OF ALZHEIMER'S DISEASE
Chemistry and Biology of gamma-Secretase as a Possible Target for Alzheimer's Disease
Gamma-Secretase Inhibition: An overview of Development of Inhibitors for Alzheimer's Disease

BETA-SECRETASE FOR TREATMENT OF ALZHEIMER'S DISEASE
BACE -
An (Almost) Perfect Target for Staving Off Alzheimer's Disease
Discovery of Memapsin 2 (BACE1), Design of Inhibitors and Drug-design Tools
Peptidomimetic BACE1 Inhibitors for Treatment of Alzheimer's Disease: Design and Evolution
Non-Peptide BACE1 Inhibitors: Design and Synthesis

PLASMEPSINS AND OTHER ASPARTIC PROTEASES AS DRUG TARGETS
The Plasmepsin Family as Antimalarial Drug Targets
Design and Synthesis of Plasmepsin Inhibitors for Treatment of Malaria
Fungal aspartic proteases as possible therapeutic targets

Buy Both and Save 25%!

+

Aspartic Acid Proteases as Therapeutic Targets (US $210.00)

-and- Protein-Ligand Interactions (US $185.00)

Total List Price: US $395.00
Discounted Price: US $296.25 (Save: US $98.75)

Add BOTH to Cart
Cannot be combined with any other offers. Learn more.